These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

96 related articles for article (PubMed ID: 31900997)

  • 1. Therapeutic effects of nebulized verapamil on chronic obstructive pulmonary disease: A randomized and double-blind clinical trial.
    Bozorgmehr R; Edalatifard M; Safavi E; Rahimi B; Ghorbani F; Abtahi H; Amini S; Pourdowlat G
    Clin Respir J; 2020 Apr; 14(4):370-381. PubMed ID: 31900997
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Clinical evaluation of nebulized verapamil in out-patients with pulmonary hypertension secondary to chronic obstructive pulmonary disease.
    Fahimi F; Pourdowlat G; Behzadnia N; Mostofi SS; Forough AS; Parto O; Esmaeili A
    Clin Respir J; 2022 Dec; 16(12):802-811. PubMed ID: 36336743
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Nebulized arformoterol in patients with COPD: a 12-week, multicenter, randomized, double-blind, double-dummy, placebo- and active-controlled trial.
    Baumgartner RA; Hanania NA; Calhoun WJ; Sahn SA; Sciarappa K; Hanrahan JP
    Clin Ther; 2007 Feb; 29(2):261-78. PubMed ID: 17472819
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Efficacy and safety of glycopyrrolate/eFlow
    Kerwin E; Donohue JF; Goodin T; Tosiello R; Wheeler A; Ferguson GT
    Respir Med; 2017 Nov; 132():238-250. PubMed ID: 28838685
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Effect of once-daily fluticasone furoate/vilanterol on 24-hour pulmonary function in patients with chronic obstructive pulmonary disease: a randomized, three-way, incomplete block, crossover study.
    Boscia JA; Pudi KK; Zvarich MT; Sanford L; Siederer SK; Crim C
    Clin Ther; 2012 Aug; 34(8):1655-66.e5. PubMed ID: 22789766
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Three-minute constant rate step test for detecting exertional dyspnea relief after bronchodilation in COPD.
    Borel B; Wilkinson-Maitland CA; Hamilton A; Bourbeau J; Perrault H; Jensen D; Maltais F
    Int J Chron Obstruct Pulmon Dis; 2016; 11():2991-3000. PubMed ID: 27942208
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Single inhaler triple therapy versus inhaled corticosteroid plus long-acting β2-agonist therapy for chronic obstructive pulmonary disease (TRILOGY): a double-blind, parallel group, randomised controlled trial.
    Singh D; Papi A; Corradi M; Pavlišová I; Montagna I; Francisco C; Cohuet G; Vezzoli S; Scuri M; Vestbo J
    Lancet; 2016 Sep; 388(10048):963-73. PubMed ID: 27598678
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A 28-day, randomized, double-blind, placebo-controlled, parallel group study of nebulized revefenacin in patients with chronic obstructive pulmonary disease.
    Pudi KK; Barnes CN; Moran EJ; Haumann B; Kerwin E
    Respir Res; 2017 Nov; 18(1):182. PubMed ID: 29096627
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Cardiac safety profile of nebulized formoterol in adults with COPD: a 12-week, multicenter, randomized, double- blind, double-dummy, placebo- and active-controlled trial.
    Nelson HS; Gross NJ; Levine B; Kerwin EM; Rinehart M; Denis-Mize K;
    Clin Ther; 2007 Oct; 29(10):2167-78. PubMed ID: 18042473
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Effect of Theophylline as Adjunct to Inhaled Corticosteroids on Exacerbations in Patients With COPD: A Randomized Clinical Trial.
    Devereux G; Cotton S; Fielding S; McMeekin N; Barnes PJ; Briggs A; Burns G; Chaudhuri R; Chrystyn H; Davies L; De Soyza A; Gompertz S; Haughney J; Innes K; Kaniewska J; Lee A; Morice A; Norrie J; Sullivan A; Wilson A; Price D
    JAMA; 2018 Oct; 320(15):1548-1559. PubMed ID: 30326124
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Pharmacodynamics, pharmacokinetics and safety of revefenacin (TD-4208), a long-acting muscarinic antagonist, in patients with chronic obstructive pulmonary disease (COPD): Results of two randomized, double-blind, phase 2 studies.
    Quinn D; Barnes CN; Yates W; Bourdet DL; Moran EJ; Potgieter P; Nicholls A; Haumann B; Singh D
    Pulm Pharmacol Ther; 2018 Feb; 48():71-79. PubMed ID: 28987804
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Effects of inhaled furosemide on exertional dyspnea in chronic obstructive pulmonary disease.
    Ong KC; Kor AC; Chong WF; Earnest A; Wang YT
    Am J Respir Crit Care Med; 2004 May; 169(9):1028-33. PubMed ID: 14977622
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The adjunctive effect of nebulized furosemide in COPD exacerbation: a randomized controlled clinical trial.
    Sheikh Motahar Vahedi H; Mahshidfar B; Rabiee H; Saadat S; Shokoohi H; Chardoli M; Rahimi-Movaghar V
    Respir Care; 2013 Nov; 58(11):1873-7. PubMed ID: 23650431
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Formoterol as dry powder oral inhalation compared with salbutamol metered-dose inhaler in acute exacerbations of chronic obstructive pulmonary disease.
    Cazzola M; D'Amato M; Califano C; Di Perna F; Calderaro E; Matera MG; D'Amato G
    Clin Ther; 2002 Apr; 24(4):595-604. PubMed ID: 12017404
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Comparison of dry powder versus nebulized beta-agonist in patients with COPD who have suboptimal peak inspiratory flow rate.
    Mahler DA; Waterman LA; Ward J; Gifford AH
    J Aerosol Med Pulm Drug Deliv; 2014 Apr; 27(2):103-9. PubMed ID: 23745526
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Efficacy and safety of the long-acting β2-agonist olodaterol over 4 weeks in Japanese patients with chronic obstructive pulmonary disease.
    Ichinose M; Takizawa A; Izumoto T; Tadayasu Y; Hamilton AL; Kunz C; Fukuchi Y
    Int J Chron Obstruct Pulmon Dis; 2015; 10():1673-83. PubMed ID: 26316741
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The role of domiciliary nebulizers in managing patients with severe COPD.
    Eiser N; Angus K; McHale S
    Respir Med; 2001 Apr; 95(4):265-74. PubMed ID: 11316108
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Comparison of nebulized budesonide and oral prednisolone with placebo in the treatment of acute exacerbations of chronic obstructive pulmonary disease: a randomized controlled trial.
    Maltais F; Ostinelli J; Bourbeau J; Tonnel AB; Jacquemet N; Haddon J; Rouleau M; Boukhana M; Martinot JB; Duroux P
    Am J Respir Crit Care Med; 2002 Mar; 165(5):698-703. PubMed ID: 11874817
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Inhaled fentanyl citrate improves exercise endurance during high-intensity constant work rate cycle exercise in chronic obstructive pulmonary disease.
    Jensen D; Alsuhail A; Viola R; Dudgeon DJ; Webb KA; O'Donnell DE
    J Pain Symptom Manage; 2012 Apr; 43(4):706-19. PubMed ID: 22168961
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Efficacy and Tolerability of an Inhaled Selective Glucocorticoid Receptor Modulator - AZD5423 - in Chronic Obstructive Pulmonary Disease Patients: Phase II Study Results.
    Kuna P; Aurivillius M; Jorup C; Prothon S; Taib Z; Edsbäcker S
    Basic Clin Pharmacol Toxicol; 2017 Oct; 121(4):279-289. PubMed ID: 28212463
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.